Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (DoubleITK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02891395
Recruitment Status : Completed
First Posted : September 7, 2016
Last Update Posted : July 10, 2019
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
Open label non-randomized multicenter phase 2 trial with direct individual benefice

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Drug: Imatinib Mesylate and Nilotinib Phase 2

Detailed Description:

Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year. Patients, who discontinue imatinib mesylate at 3 months for lack of response (no response = stable disease), those who experience progression at any time, those who relapse after an initial response at any time or those who discontinue for toxicity at any time, will go to the salvage phase.

Salvage phase:

Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (Graft Versus Host, GVH) Did Not Respond to Imatinib Mesylate.
Actual Study Start Date : December 24, 2012
Actual Primary Completion Date : July 26, 2017
Actual Study Completion Date : July 26, 2017


Arm Intervention/treatment
Experimental: open-label

Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.

Salvage phase:

Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year.

Drug: Imatinib Mesylate and Nilotinib

For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.

For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52.





Primary Outcome Measures :
  1. Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate (IM) [ Time Frame: Between Baseline and minimum 12 weeks of treatment ]
    Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate (IM)


Secondary Outcome Measures :
  1. Best response to IM within 12 months and the duration of this response [ Time Frame: From 12 to 52 weeks of Imatinib Mesylate treatment ]
  2. Best response rate to Nilotinib within 12 months and the duration of this response [ Time Frame: From 12 to 52 weeks of Nilotinib treatment ]
  3. use of systemic secondary treatment due to intolerance to IM [ Time Frame: From baseline to 12 weeks of IM treatment ]
    measure intolerance by IM failure

  4. use of systemic secondary treatment due to intolerance to Nilotinib [ Time Frame: From baseline to 12 weeks of Nilotinib treatment ]
    measure intolerance by Nilotinib failure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Induction phase (IM):

  • Patients aged ≥18 years to 75 years
  • Patients who underwent allo-SCT for a hematological disorder
  • Body weight ≥ 40 Kg.
  • Confirmed diagnosis of cGVHD resistant to at least one systemic immunosuppressive therapy. The diagnosis of cGHVD should be based on the NIH Working Group Consensus (www.asbmt.org/gvhd/index.htm). Grading of cGVHD will be based on clinical manifestations including:

    1. ocular, oral and mucosal symptoms;
    2. performance status;
    3. evaluation of pulmonary functions;
    4. cutaneous evaluation;
    5. evaluation of musculo-skeletal manifestations;
    6. evaluation of liver involvement;
  • Any source of hematopoietic stem cell is allowed
  • Both myeloablative and nonmyeloablative conditioning regimens are authorized.
  • Absence of contra-indications to the use of IM or Nilotinib
  • Patient having French health care coverage
  • Female patients of childbearing potential must have before initiation of study drug and agree to have efficient contraceptive precautions throughout the trial and for 3 months after the end of the trial.
  • Signed informed consent.

Salvage phase (Nilotinib) :

Patients enrolled in the first phase and who failed to IM:

  • Patients, who discontinue imatinib mesylate at 3 months for lack of response (no response = stable disease),
  • those who experience progression at any time,
  • those who relapse after an initial response at any time
  • or those who discontinue for toxicity at any time.

Exclusion Criteria:

  • Patient developing acute GVHD (whether early or "late onset" form)
  • First episode of cGVHD
  • Patient who received IM or Nilotinib treatment or any other TKI after transplant 3 months before the inclusion on the study
  • Patient treated by TKI for a GVHD
  • Contra-indication to IM or Nilotinib
  • Neutropenia < 0.5 G/L
  • Uncontrolled systemic infection which can be associated, according to the investigator, to an enhanced risk of patient's death during the first month of treatment
  • Severe neurological or psychiatric disorders
  • Pregnancy or lactation
  • Known uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction < 40% (cardiac tests as clinically indicated)
  • Recurrence of cancer for which the transplant was done except for presence of minimal residual disease by PCR
  • Patients with secondary malignancy ≤ 2 years prior study-entry except:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Prostate cancer (Tumor, Node, Metastasis [TNM] stage T1a or T1b)
  • Patients in emergency situation
  • Patients kept in detention
  • Patients unable or unwilling to comply with the protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02891395


Locations
Show Show 22 study locations
Sponsors and Collaborators
University Hospital, Lille
Novartis
Investigators
Layout table for investigator information
Principal Investigator: YAKOUB-AGHA Ibrahim, MD University Hospital, Lille
Layout table for additonal information
Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT02891395    
Other Study ID Numbers: 2009_18
2012-000770-36 ( EudraCT Number )
First Posted: September 7, 2016    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Keywords provided by University Hospital, Lille:
allogeneic stem cell transplantation
imatinib Mesylate
Nilotinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Chronic Disease
Immune System Diseases
Disease Attributes
Pathologic Processes
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action